Repligen Corporation (NASDAQ: RGEN) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership and dividends.

Valuation & Earnings

This table compares Repligen Corporation and Eagle Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Repligen Corporation $113.32 million 13.62 $29.54 million $0.51 81.02
Eagle Pharmaceuticals $245.88 million 3.40 $83.99 million $5.95 9.27

Eagle Pharmaceuticals has higher revenue and earnings than Repligen Corporation. Eagle Pharmaceuticals is trading at a lower price-to-earnings ratio than Repligen Corporation, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Repligen Corporation and Eagle Pharmaceuticals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Repligen Corporation 0 2 2 0 2.50
Eagle Pharmaceuticals 1 0 3 0 2.50

Repligen Corporation presently has a consensus price target of $41.00, suggesting a potential downside of 0.77%. Eagle Pharmaceuticals has a consensus price target of $73.25, suggesting a potential upside of 32.84%. Given Eagle Pharmaceuticals’ higher probable upside, analysts clearly believe Eagle Pharmaceuticals is more favorable than Repligen Corporation.

Risk and Volatility

Repligen Corporation has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500. Comparatively, Eagle Pharmaceuticals has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500.

Institutional and Insider Ownership

99.5% of Repligen Corporation shares are owned by institutional investors. 1.5% of Repligen Corporation shares are owned by company insiders. Comparatively, 19.5% of Eagle Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Repligen Corporation and Eagle Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Repligen Corporation 15.61% 9.90% 5.93%
Eagle Pharmaceuticals 39.32% 66.30% 48.44%

Summary

Eagle Pharmaceuticals beats Repligen Corporation on 10 of the 13 factors compared between the two stocks.

Repligen Corporation Company Profile

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products. It provides Protein A ligands, a component of Protein A chromatography resins (media) used in the purification of virtually all monoclonal antibody (mAb)-based drugs on the market or in development. Its chromatography portfolio includes various products used in the downstream purification and quality control of biological drugs. Its OPUS pre-packed chromatography columns (PPCs) are used in the purification of clinical-stage biologics. Its filtration products include XCell Alternating Tangential Flow (ATF) Systems and Sius tangential flow filtration (TFF) cassettes. Sius TFF cassettes are used to concentrate clinical and commercial-stage biologic drugs.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka. Its advanced candidates include EP-3101 (bendamustine Resistance Temperature Detectors (RTD)) (EP-3101), EP-4104 (dantrolene sodium for exertional heat stroke (EHS)) (EP-4104), EGL-4104-C-1702 (dantrolene sodium for drug induced hyperthermia), EP-5101 (pemetrexed) (EP-5101) and EGL-5385-C-1701 (fulvestrant). Its product portfolio focuses on oncology, critical care and orphan diseases. Bendamustine is an alkylating agent approved for use in chronic lymphocytic leukemia (CLL), and indolent B-cell non-Hodgkin’s lymphoma (NHL), that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Receive News & Stock Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related stocks with our FREE daily email newsletter.